Immune-mediated colitis secondary to treatment with nivolumab-ipilimumab in a patient with stage IV kidney cancer: what do we do when corticosteroids fail?

Rev Esp Enferm Dig. 2022 Sep;114(9):554-555. doi: 10.17235/reed.2022.8632/2022.

Abstract

52-year-old male. The patient had a stage IV renal carcinoma with bone metastases. He started first-line treatment with nivolumab (3 mg/kg) associated with ipilimumab (1 mg/kg). After two cycles of treatment, the patient reported hemorrhagic diarrhoea (7 to 10 stools daily), with visceral nociceptive abdominal pain of moderate intensity and oral intolerance.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / pathology
  • Colitis* / chemically induced
  • Humans
  • Ipilimumab / adverse effects
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / pathology
  • Male
  • Melanoma* / pathology
  • Nivolumab / adverse effects

Substances

  • Adrenal Cortex Hormones
  • Ipilimumab
  • Nivolumab